DelSiTech Ltd will attend LSX Investival in London, 16 Nov 2026

DelSiTech Ltd is ready for the next step in its journey.

We are pleased to announce that DelSiTech Ltd will attend LSX Investival in London, bringing together leading life sciences companies, investors and industry experts to explore investment opportunities, partnerships and the future of healthcare innovation.

On Monday at 13:45, in the Biotech Growth Stream, DelSiTech's CEO, Laura Chirica, PhD, will present the company's investment case and strategic direction.

Our proprietary Silica Matrix® technology provides a versatile platform for developing ultra-long-acting injectable medicines, with the potential to transform treatment across several therapeutic areas. We are now preparing to advance our internal pipeline, building on the platform's potential to deliver:

• Sustained and precisely controlled drug release
• Extended dosing intervals and fewer injections
• Improved treatment convenience and patient adherence
• Scalable manufacturing solutions for pharmaceutical development

Our programs target significant unmet medical needs, including obesity, psychiatric disorders and post-operative pain.

Our ambition is clear: to translate the potential of Silica Matrix® into innovative medicines that make a meaningful difference for patients.

We warmly invite investors, potential partners and industry colleagues to join the presentation and connect with Laura during the event.

We look forward to meeting you in London!